Key facts
- Hemotune’s last known valuation is $40.2M (Dec 2025).
- It has raised $35.4M; the latest was Later Stage VC ($17.4M) in Dec 2025.
- Notable investors include Venture Kick, Innosuisse, Zürcher Kantonalbank, Venture (Switzerland), Belmondo Family Office — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Hemotune
- ·The full record, as it builds
Funding rounds
No funding rounds for Hemotune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hemotune
Developer of a therapeutic blood purification platform designed to develop blood purification technology. The company's platform offers treatments based on magnetic beads that allow selective and efficient removal of large biomolecules directly from blood and focuses on the immunological aspects of sepsis that tackle multiple disease pathways, enabling patients to get the required treatment for blood-related diseases.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2016
- Employees
- 25
- Website
- hemotune.com/
- Ownership
- Privately Held (backing)
Hemotune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hemotune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hemotune in its N-PORT filings yet. We sweep new filings monthly.